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Previous work has demonstrated that the hormone prolactin promotes oligodendrocyte precursor proliferation and
remyelination following lysolecithin-induced demyelination of the mouse spinal cord. Prolactin, however, can elicit
pro-inflammatory responses, and its use in the prototypical demyelinating and inflammatory condition, multiple
sclerosis (MS), should thus be approached cautiously. Here, we sought to determine whether recombinant prolactin
could alter the course of experimental autoimmune encephalomyelitis (EAE), an inflammatory animal model of MS.
Consistent with previous literature, we found that prolactin activated leukocytes in vitro. Daily treatment with prolactin
from around the time of onset of clinical signs, for 9 (days 9 to 17) or 25 (days 9 to 33) days did not increase clinical or
histological signs of EAE over that of vehicle-treated mice. Instead, the combination of prolactin and a suboptimal dose
of recombinant murine interferon-β resulted in (days 9 to 17 group) or trended towards (days 9 to 33 group), a greater
amelioration of clinical signs of EAE, compared to either treatment alone or to vehicle controls. Histological analyses
corroborated the clinical EAE data. These results suggest that prolactin may be beneficial when administered in
combination with interferon-β in MS.
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Multiple sclerosis (MS) is a chronic T and B cell-mediated
inflammatory disorder of the central nervous system
(CNS) associated with progressive oligodendrocyte and
neuronal loss, axonal degeneration, and demyelination [1].
Prolactin is a pituitary hormone that stimulates milk pro-
duction in mammals, and it may be implicated in the
pathophysiology of MS [2,3]. Interestingly, MS tends to
undergo remission during mid-late pregnancy, where pro-
lactin levels are known to be at their peak during the third
trimester of pregnancy [4-7]. Breastfeeding promotes fur-
ther prolactin release, even though levels would otherwise
fall post-partum [8,9]. Importantly, a recent meta-analysis
(12 studies; n = 1,558) found that women with MS who
breastfed were almost half as likely to experience a post-
partum relapse compared to women who did not [10].* Correspondence: vyong@ucalgary.ca
†Equal contributors
Hotchkiss Brain Institute and the Department of Clinical Neurosciences,
Cumming School of Medicine, University of Calgary, 3330 Hospital Drive NW,
Calgary, AB T2N 4N1, Canada
© 2015 Zhornitsky et al.; licensee BioMed Cen
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.The data are even more compelling when considering only
studies that examined exclusive breastfeeding [11,12].
In animals, our group showed that pregnant mice have
an enhanced ability to remyelinate lysolecithin-induced
white matter lesions [13]. This was observed via an in-
crease in proliferation of oligodendrocyte precursor cells,
oligodendrocyte generation, expression of myelin basic
protein, and in the number of myelinated axons - effects
that were stimulated by prolactin infusion. Others have
revealed that prolactin may possess pro-inflammatory
properties. For example, there is evidence that prolactin
promotes the activation of B cells cultured from the
blood of MS patients [14]. Additionally, T cell cultures
treated with prolactin have an elevated T helper 1 pro-
inflammatory profile and decreased suppressive function
of regulatory T cells [15]. Preclinical studies suggest that
reduction of prolactin levels via treatment with dopamine
D2 agonists (bromocriptine and dihydroergocryptine) re-
duces severity of experimental autoimmune encephalomy-
elitis (EAE), an animal model of MS [16-19]. On the other
hand, a recent study revealed that prolactin receptor- andtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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compared with littermate control mice, but with full
clinical severity [20]. Importantly, no study of the direct
administration of purified prolactin in EAE has been con-
ducted to date.
The present study examined the effect of purified re-
combinant prolactin in EAE at different periods sur-
rounding the onset of neurological signs and with/
without concomitant interferon-β (IFN-β), a standard
disease modifying therapy in MS. The addition of IFN-β
was explored because of the potential pro-inflammatory
properties of prolactin, making it prudent to combine its
use with an immunomodulator commonly used in MS.
Methods
Recombinant murine prolactin was tested in virgin
C57BL/6 female mice aged 8 to 10 weeks. EAE was
induced at day 0 by 50 μg myelin oligodendrocyte glyco-
protein (MOG), peptide 35-55, emulsified in Complete
Freund’s Adjuvant supplemented with 4 mg/kg of myco-
bacterium, as described elsewhere [21]. Mice were also
administered two intraperitoneal injections of pertussis
toxin (List Biological Labs, Hornby, ON, USA), on days
0 and 2. Intraperitoneal injections of 20 μg/mouse of
prolactin (Harbor-UCLA, Torrance, CA, USA) were ap-
plied every morning, either for 9 (days 9 to 17) or 25
(days 9 to 33) consecutive days. Previously, we found
that the same dosing regimen promoted myelin repair in
virgin female mice of a similar age. In the 9-day experi-
ment, while mice were treated from days 9 to 17, they
were sacrificed on day 21. In the 25-day experiment,
mice were sacrificed on the day of the last treatment
itself. Day 9 was the time period when onset of clinical
signs of EAE was anticipated. Groups of mice also re-
ceived suboptimal doses (20,000 IU/mouse) of recom-
binant murine IFN-β (PBL Biomedical Laboratories,
Piscataway, NJ, USA) administered subcutaneously once
every 2 days, alone or in combination with prolactin.
Vehicle was phosphate-buffered saline.
EAE clinical disease scores were obtained by using a
15-point scale that totals the degree of disability of the
tail (scored from 0 to 2) and all four limbs (each limb
scored from 0 to 3) [22]. When the sum of scores (bur-
den of disease) was tabulated, this represents the daily
clinical score per mouse, added over the course of the
experiment for that mouse.
Histological analyses were performed on spinal cord
specimens retrieved at the end of treatment. The degree
of inflammation and demyelination of the spinal cord
was assessed through hematoxylin and eosin and luxol
fast blue (H&E/LFB), as previously described [21]. Ani-
mal studies were performed according to ethical policies
outlined by the Canadian Council for Animal Care and
the University of Calgary.Antigen-recall assay
Mice were sacrificed, and lymph nodes were removed on
day 10 after MOG immunization. Lymph nodes (LNs) were
dissociated, and single cell suspensions were collected in
phosphate-buffered saline. LN cells were plated in round-
bottom plates at a density of 250,000 cells/100 μl in RPMI
containing 1% mouse serum (Invitrogen, Carlsbad, CA,
USA). The LN populations served to provide T cells for
subsequent antigen-recall proliferation. Antigen-presenting
cells (APCs) were harvested from spleens taken from non-
immunized animals. Spleens were dissociated and sub-
jected to red blood cell lysis. Cells were re-suspended in
RPMI containing 1% mouse serum. APCs were irradiated
at room temperature with a Gamma Cell 1000 (Nordion
International Inc., Vancouver, Canada) using Cs-137 for 14
min at 3,000 rad, which was then followed by incubation of
the APC cells with 20 μg/ml MOG 35-55 for 30 min at
4°C. The APCs (250,000 APCs/100 μl) were then added to
the LN cells described above for a total of 500,000 cells/
well. Recombinant mouse prolactin was added (1, 10, and
30 nM) and incubated for 3 days. The doses were chosen
from previous literature that had suggested a pro-
inflammatory role for prolactin in vitro on T lymphocytes.
3H-thymidine was added 18 h before the harvesting and
collection of cells for measurement of thymidine uptake.
Cells were pulsed with 1 μCi of [H3] thymidine (Perkin
Elmer, Waltham, MA, USA) to determine the proliferative
state of the cultures. After incubation, cells were harvested
using a PHD cell harvester (Brandel Inc., Gaithersburg,
MD, USA) and [H3] thymidine incorporation was deter-
mined by using a Beckman LS3801 scintillation counter
(Beckman Coulter, Mississauga, Canada).
Statistics
Statistical analysis was performed using SPSS Statistics
v.22.0 (IBM Corporation, Armonk, NY, USA, 2013).
Statistical differences between groups were evaluated
using a non-parametric Kruskal-Wallis analysis. Multiple
comparisons were performed using the Mann-Whitney
U test. In all tests, P ≤ 0.05 was considered statistically
significant.
Results
Prolactin promotes MOG antigen-specific proliferative
responses
Lymphocytes harvested from the lymph nodes of mice
sacrificed at day 10 post-MOG immunizations revealed
increased lymphocyte recall responses to MOG antigen
(data not shown). Prolactin significantly increased the
overall proliferative index of cells responding to a second
exposure to MOG peptide. The addition of prolactin in-
creased thymidine uptake by splenocytes in a dose-
dependent manner with the maximal response obtained
with 30 nM prolactin (data not shown).
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days 9 to 17 with sacrifice at day 21
The pro-remyelinating effects of prolactin suggest its
potential use in demyelinating conditions including MS
[13]. However, given the potential of prolactin to pro-
mote pro-inflammatory responses in T and B lympho-
cytes [14,15], it is important to consider that prolactin
may increase disease severity of MS or its model, EAE.
Thus, we treated EAE-afflicted mice with recombinant
prolactin from their onset of clinical signs, daily for 9
days (days 9 to 17), with animals killed at day 21 for
histology. The dose of 20 μg prolactin/mouse/day was
chosen as this was the pro-remyelinating dose in the ly-
solecithin demyelinating model in mice [13]. We found
that EAE-afflicted mice treated with vehicle attained
peak clinical severity of between 4 and 6 on the 15-point
scale [22], representing tail and hind-limb disability
(Figure 1A); this modest disease severity provided room
to reveal a pro-disease exacerbating effect, as EAE-
afflicted mice often have involvement of forelimb disabil-
ity in other experiments (data not shown). Prolactin
treatment did not exacerbate EAE clinical severity
over that of vehicle-treated EAE mice (Figure 1A), and a
suboptimal dose of recombinant murine IFN-β also did
not affect EAE clinical severity. Interestingly, the com-
bination of prolactin and IFN-β resulted in a reduction
of sum of daily clinical scores (Figure 1A) to an average
of 2 on the 15-point scale, representing tail disability but
without hind-limb involvement.
To better document the disease-lowering effect of
prolactin, we added the daily clinical score over the
course of the 21 days on a per mouse basis; this sum of
scores reflects the burden of clinical disease for that
mouse over the course of the experiment. The sum of
EAE scores was significantly different between the four
groups (χ2 = 10.941; P = 0.012; Figure 1B), and post hoc
analyses demonstrate that the combination of prolactinFigure 1 The combination of prolactin (PRL) and IFN-β attenuated EA
(A) Mean clinical EAE scores from Tx days 9 to 17 with sacrifice at day 21 (
sacrifice at day 21, with each circle, square, or triangle depicting a separate an
animals, and four each of IFN-β alone or the combination group.and IFN-β resulted in significantly lower sum of scores,
relative to prolactin-alone (Z = −2.558; P = 0.011), IFN-β-
alone (Z = −2.323; P = 0.020), and vehicle (Z = −2.652; P =
0.008) (Figure 1B). The difference among the four groups
was still significant when analyzing sum of scores from
days 9 to 17 only (χ2 = 12.01; P = 0.007).
Animals were sacrificed at day 21, and H&E/LFB histo-
logical analyses encompassing general histology, demyelin-
ation, and cellular infiltrates were conducted (Figure 2).
There was a borderline significant difference in histo-
logical scores (χ2 = 7.594; P = 0.055). Post hoc analysis re-
vealed that the combination of prolactin and IFN-β
resulted in significantly lower histological scores, com-
pared to vehicle (Z = −2.132; P = 0.033) and IFN-β-alone
(Z = −2.309; P = 0.021). There was no significant difference
between the combination of prolactin and IFN-β versus
prolactin-alone in terms of histological scores.Extended treatment with prolactin (days 9 to 33) did not
promote EAE disease severity
Given that the use of prolactin may be for an extended
period in chronic conditions such as MS, we sought to
address a longer treatment period of EAE-afflicted mice
with prolactin. From day 9, daily treatment with prolac-
tin, and every other day of IFN-β, was effected until day
33. In this experiment, the EAE-afflicted mice treated
with vehicle had a higher disease score, compared to the
days 9 to 21 experiment, of between 6 and 8 on the 15-
point scale; this represents disability occurring in the tail
and hind limbs and also involvement of the forelimbs.
Perhaps because of this higher severity, prolactin-alone,
or prolactin plus IFN-β, did not result in a significant re-
duction in clinical score compared to vehicle-treated
mice, although a tendency towards reduction was ob-
served (χ2 = 4.830; P = 0.185; Figure 3A,B). Importantly,
prolactin did not enhance disease severity.E clinical severity, relative to vehicle and either treatment alone.
bars indicate SEM). (B) Sum of EAE scores from Tx days 9 to 17 with
imal: **P < 0.01; *P < 0.05. There were seven vehicle mice, six PRL-alone
Figure 2 The combination of PRL and IFN-β reduced histopathology in the spinal cord. Histology at day 21 for a representative vehicle mouse
(histology score = 4) (A) or from a representative mouse in the combination group (B) (histology score = 2). The × 10, ×20, and × 40 depict the original
magnification as captured by the respective objective lens. (C) Mean histology scores from day 21, where each display is of a separate mouse: *P< 0.05.
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ence detected (Figure 4; χ2 = 8.477; P = 0.037). Multiple
comparisons revealed that the combination of prolactin
plus IFN-β resulted in significantly lower histology
scores, relative to vehicle (Z = −2.492; P = 0.013), andFigure 3 A trend towards reduction of clinical scores was observed in
(A) Mean clinical EAE scores in animals treated from Tx days 9 to 33 (bars i
significance was not found although there was a tendency for the prolacti
scores. There were seven mice each in the vehicle, prolactin-alone, or comthere was a trend towards reduced histology scores,
compared to IFN-β-alone (Z = −1.868; P = 0.062). There
was no significant difference between the combination
of prolactin and IFN-β and prolactin-alone in terms of
histology scores.EAE mice on long-term prolactin or combination treatment.
ndicate SEM). (B) Sum of EAE scores from Tx days 9 to 33. Statistical
n-alone, or combination treatment group to have lower clinical disease
bination group, while there were five animals in the IFN-β-alone group.
Figure 4 The combination of PRL + IFN-β attenuated histology scores in the spinal cord. (A) Histology from day 33, depicting inflammation
and demyelination, in a representative vehicle mouse (histology score = 4), or from a representative animal in the combination group (B) (score = 2).
(C) Mean histology scores from day 33, where each circle, square, or triangle is of a separate mouse. *P < 0.05.
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Previous work has demonstrated that the hormone prolac-
tin promotes the proliferation of oligodendrocyte precur-
sor cells and remyelination in the lysolecithin model of
demyelination in mice [13]. That study also showed that
white matter changes occurred in the maternal CNS,
and these changes were initiated during early pregnancy
and include increases in proliferation of oligodendrocyte
precursor cells, oligodendrocyte generation, expression of
myelin basic protein, and, ultimately, an increase in the
number of myelinated axons. In addition, we found that
prolactin signaling was necessary and sufficient for the re-
generative effects of pregnancy and that prolactin treat-
ment of virgin mice enhanced their remyelinating capacity
following demyelination [13]. Pro-regenerative effects were
also observed by Möderscheim et al. [23] wherein prolac-
tin exerted trophic and pro-proliferative effects on glia.
The pro-remyelinating capacity of prolactin suggests its
utility in demyelinating conditions such as MS, except thatthis must be weighed against reports that prolactin can
have pro-inflammatory roles. A pro-inflammatory role for
prolactin has been reported for T lymphocytes previously
by stimulating splenocytes in vitro using concanavalin A
[17,18]. These cells displayed lymphoproliferation in a
dose-dependent manner that could be antagonized with
the use of corticosteroids with lymphoproliferation ob-
served at concentrations of 5 nM but not 1 nM prolactin
in culture [24]. Additionally, the proliferation of spleno-
cytes and thymocytes stimulated with anti-CD3 was fur-
ther promoted in the presence of 10 nM ovine prolactin
as assessed by thymidine uptake [25]. In both cases, the
antigen non-specific response was measured and these
effects were mimicked by the addition of growth hormone
suggesting that prolactin may act similarly to this hor-
mone as a mitogen for cell proliferation. It remains to be
shown whether prolactin plays a role in stimulating mem-
ory or recall responses. Here, the mitogenic effect of pro-
lactin seen previously with anti-CD3 and concanavalin A
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suggesting that prolactin may be pro-proliferative when
present during antigen-recall in an ongoing immune
response.
A dopaminergic pathway in the hypothalamus-pituitary
axis controls the production of prolactin. Treatment with
D2 agonists lowers prolactin levels, and a number of stud-
ies have reported beneficial effects of prolactin suppres-
sion in EAE. In one study, bromocriptine given 1 week
before immunization significantly decreased serum prolac-
tin levels, and this was accompanied by an inhibition of
disease progression in acute EAE [16]. In that study, im-
munocompetence of bromocriptine-treated animals was
restored by additional treatment with either prolactin or
growth hormone. A similar study by Riskind et al. [17] re-
vealed that induction of acute EAE resulted in a threefold
rise in prolactin levels on day 4 after immunization and
maintained elevated levels on day 10 before the onset of
neurological signs. Bromocriptine significantly reduced
the rise in prolactin levels and inhibited disease progres-
sion when initiated 1 week after immunization and also in
late disease. Another report administered bromocriptine
after the onset of clinical signs in acute as well as in
chronic relapsing EAE [19]. Their results revealed that
bromocriptine suppressed prolactin levels and reduced the
severity and duration of clinical signs in acute EAE and
the duration of the second attack in chronic EAE. Finally,
there is evidence that dihydroergocryptine induced a large
reduction of prolactin levels accompanied by a significant
improvement in neurological signs of acute EAE when
given 2 days before immunization [18]. Taken together,
these studies suggest that reduction of prolactin levels
by selective D2 agonists is effective at reducing disease
severity in acute and chronic EAE, supporting a pro-
inflammatory effect of prolactin. However, a small clinical
trial (n = 18) did not find a benefit of bromocriptine in
RRMS and progressive MS patients [26]. More recent lit-
erature suggests that dopamine may be directly linked to
immunomodulation - for example, by inhibiting activated
T cell function, modulating Tregs, and altering B cell func-
tion [27]. Thus, suppression of prolactin in the aforemen-
tioned studies may not be the primary mechanism via
which dopamine agonists reduce EAE severity. Taken to-
gether, it is currently not clear whether suppression of
physiologic levels of prolactin via therapy with D2 agonists
would benefit patients with MS.
A recent study revealed that prolactin receptor-
and prolactin-knockout mice develop a delayed onset
EAE, compared with littermate control mice, but
with full clinical severity [20]. Because prolactin re-
ceptor knockouts have been shown to be hyperpro-
lactinemic, these data suggest that neither high nor
low prolactin levels significantly impact EAE. The
data are correspondent with previous results showingthat prolactin receptor-knockout mice develop nor-
mal immune function [28,29].
In view of the uncertainty of the impact of prolactin in
MS, we have reviewed the literature and concluded that
there is no compelling argument against the use of pro-
lactin in MS [3]. In support, post-partum data of breast-
feeding where prolactin levels are expected to be high
have indicated that there may be a protective effect of
breast-feeding against MS relapses [10-12].
Nonetheless, the use of prolactin in MS must be
approached cautiously, and it would be prudent to com-
bine its use with an immunomodulator commonly used
in the condition. In the current study, we have used
purified recombinant prolactin in EAE. Our data shows
that recombinant prolactin-alone had no effect on EAE
clinical scores during treatment for 9 or 25 days. Indeed,
prolactin did not exacerbate EAE - as would be pre-
dicted based on its pro-inflammatory properties - but
may have exerted further beneficial properties not appar-
ent in the overwhelming inflammatory and potentially
pro-proliferative mechanisms of EAE. With this in mind,
we examined the effect of prolactin in the presence of
suboptimal doses of the therapeutic immunomodulator
IFN-β. Our data suggests that the mixture of these two
therapies given over a protracted period after disease
onset provides a benefit not observed with either of the
single treatment therapies. In addition, observation of
spinal cord histopathology of these mice suggests that
combination therapy decreased the overall disease burden
as reflected by inflammatory infiltrates. Consequently, it is
possible that IFN-β counteracted a pro-inflammatory ef-
fect of prolactin, thus allowing for the putative remyelinat-
ing properties of prolactin to take effect - as previously
shown by our group in the lysolecithin model [13].
We were unable to determine whether the improvement
in clinical scores in response to combined prolactin and
IFN-β treatment could be attributed to remyelination. The
EAE model is notoriously difficult to evaluate remyelina-
tion, as lesions appear at unpredictable locations, and
it is therefore not trivial to address the evolution of de-
myelination and its subsequent repair. Thus, while the
histological analyses (Figures 2 and 4) show reduced in-
flammation and demyelination in response to combined
prolactin and IFN-β treatment, to what extent remyelina-
tion has occurred remains unclear.
In conclusion, we sought to determine whether prolac-
tin could alter the course of EAE, either when used
alone, or in combination with IFN-β. We found that the
combination of prolactin and IFN-β during the 9-day
treatment period resulted in a greater amelioration of
clinical signs and histological scores of EAE compared
to either treatment alone. The combination therapy also
resulted in significantly less inflammatory infiltrates with
prolonged 9- to 33-day treatment. Consequently, in light
Zhornitsky et al. Journal of Neuroinflammation  (2015) 12:55 Page 7 of 7of the seemingly beneficial effects of breast-feeding on
MS symptomatology, and our promising results in the
lysolecithin and EAE models, future trials of prolactin in
MS may be warranted. Either prolactin itself, or medications
that elevate prolactin levels, may be considered.
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